Hypercalcemia secondary to malignancy is rare in children and the majority is caused by tumor-produced parathyroid hormone-related protein (PTHrP). We report a case of hypercalcemia refractory to bisphosphonate and corticosteroid therapy, but responsive to denosumab. A 17-year-old boy with epidermolysis bullosa (EB) and advanced squamous cell carcinoma (SCC) of the left leg was referred with se...

E-mail: [email protected] References 1. SILVE C: Hereditary hypophosphatasia and hyperphosphatasia. Curr Opin Rheumatol 1994; 6: 3369. 2. GRAEPEL P, BENTLEY P, FRITZ H, MIYAMOTO M, SLATER SR: Reproduction toxicity studies with pamidronate. Arzneimittelforschungnn 1992; 42: 654-67. 3. BLACK AJ, TOPPING J, DURHAM B, FARQUHARSON RG, FRASER WD: A detailed assessment of alterations in bone turno...

Previous studies show that surface immobilized bisphosphonates improve the fixation of stainless steel screws in rat tibia after 2-8 weeks of implantation. We report here about the immobilization of a potent bisphosphonate, zoledronate, to crosslinked fibrinogen by the use of another technique, i.e. ethyl-dimethyl-aminopropylcarbodiimide (EDC)/imidazole immobilization. Bone fixation of zoledron...

Few data are available on the ability of bone markers to predict the symptomatic response to bisphosphonate therapy in patients with painful bone metastases. We evaluated the levels of bone markers in patients with bone metastases receiving pamidronate and determined the corresponding analgesic response. Forty-two patients were administered two two-week cycles of intravenous pamidronate 60 mg/w...

The cytotoxic function of polyclonal expanded γ/δ T cells against pamidronate-treated cervical cancer cells in vitro and in vivo were determined. The γ/δ T cells were isolated and purified from PBMCs by using miniMACS and were later treated with 10 μM pamidronate. The expansion of γ/δ T cells was 15 times more than the non-stimulated cells. Among the expanded γ/δ T cells, 47% were Vγ9/Vδ2 T cel...

Immobilization-related hypercalcaemia is an uncommon but important condition being associated not infrequently with both urolithiasis and osteoporosis. In this study 5 patients who had been immobilized for a mean of 3 months and had a mean adjusted serum calcium of 3.15 mmol/l were treated with doses of intravenous pamidronate ranging between 10 mg and 45 mg. All patients became normocalcaemic ...

PURPOSE Mortality from breast cancer has decreased in large part because of adjuvant chemotherapy. Sequelae of therapy include ovarian failure and bone loss, loss that would increase these patients' risk of fracture with aging. In this study, we assessed the efficacy of pamidronate in preventing such loss. PATIENTS AND METHODS The study was a 1-yr randomized, double-blind, placebo-controlled ...

BACKGROUND Bisphosphonates (BPs) are potent antiresorptive agents used to treat osteoporosis and the complications associated with malignant bone metastasis. The aim of this study was to evaluate the incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) using the Japanese Adverse Drug Event Report (JADER) database. In particular, we focused on the time-to-onset profile of BRONJ. ...

BACKGROUND Bisphosphonates are a main component in the therapy of osteoporosis and other bone resorptive diseases. Previous studies have shown a positive effect of systemically applied bisphosphonates on fracture healing. Nevertheless high doses are related to side effects like osteonecrosis of the jaw, nephrotoxis and gastrointestinal symptoms. In this study we investigated the effect of local...

Treatment with bisphosphonates has brought significant clinical improvements for children and adolescents suffering from moderate to severe forms of osteogenesis imperfecta (OI). Benefits include decreased pain, lower fracture incidence, and better mobility. Among the various bisphosphonates, intravenous pamidronate has been studied in most detail. It is unclear whether oral bisphosphonates are...